Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KYNU | Q16719 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.53 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | GRM8 | O00222 | 1/20 | 0.52 |
| ▸ | GRM6 | O15303 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1512921 | 1.00 | KYNU (0.60) | KYNUKDM4ELMNAHIF1AHSD17B10 | |
| SCHEMBL29061153 | 1.00 | KYNU (0.60) | KYNUKDM4ELMNAHIF1AHSD17B10 | |
| SCHEMBL29725697 | 1.00 | KYNU (0.60) | KYNUKDM4ELMNAHIF1AHSD17B10 | |
| SCHEMBL31564921 | 1.00 | KYNU (0.60) | KYNUKDM4ELMNAHIF1AHSD17B10 | |
| Hydrochloric Acid SCHEMBL4375905 | 0.98 | KYNU (0.58) | KYNUKDM4ELMNAHIF1AHSD17B10 | |
| SCHEMBL1352076 | 0.84 | ADRB1 (0.52) | KYNUKDM4ELMNAHIF1AHSD17B10 | |
| SCHEMBL1352077 | 0.84 | ADRB1 (0.52) | KYNUKDM4ELMNAHIF1AHSD17B10 | |
| SCHEMBL11214577 | 0.82 | ADRB1 (0.50) | KYNUKDM4ELMNAHIF1AHSD17B10 | |
| SCHEMBL11346311 | 0.80 | CPN1 (0.59) | KYNUKDM4ELMNAHIF1AHSD17B10 | |
| SCHEMBL28282072 | 0.79 | LMNA (0.67) | KYNUKDM4ELMNAHIF1ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360175-A1 | PEPTIDE DERIVATIVES AND RELATED USES AS OREXIN AGONISTS | OXFORD FINANCE LLC | 2024-10-31 | — | — | US | claimed |
| WO-2023017180-A1 | PEPTIDE DERIVATIVES AND RELATED USES AS OREXIN AGONISTS | OREXIA THERAPEUTICS LIMITED (GB) | 2023-02-16 | — | — | WO | claimed |
| US-20260116923-A1 | CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS | MERCK SHARP & DOHME LLC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20250277001-A1 | PEPTIDE DERIVATIVES AND RELATED USES AS OREXIN AGONISTS | CENTESSA PHARMACEUTICALS UK LTD (GB) | 2025-09-04 | — | — | US | disclosed |
| US-20250213735-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2025-07-03 | — | — | US | disclosed |
| EP-4554968-A1 | PEPTIDE DERIVATIVES AND RELATED USES AS OREXIN AGONISTS | Centessa Pharmaceuticals (UK) Limited (GB) | 2025-05-21 | — | — | EP | disclosed |
| US-20240360175-A1 | PEPTIDE DERIVATIVES AND RELATED USES AS OREXIN AGONISTS | OXFORD FINANCE LLC | 2024-10-31 | — | — | US | disclosed |
| WO-2024040237-A1 | PEPTIDE DERIVATIVES AND RELATED USES AS OREXIN AGONISTS | CENTESSA PHARMACEUTICALS (OREXIA) LIMITED (GB) | 2024-02-22 | — | — | WO | disclosed |
| WO-2024040245-A1 | PEPTIDE DERIVATIVES AND RELATED USES AS OREXIN AGONISTS | CENTESSA PHARMACEUTICALS (OREXIA) LIMITED (GB) | 2024-02-22 | — | — | WO | disclosed |
| WO-2024040237-A1 | PEPTIDE DERIVATIVES AND RELATED USES AS OREXIN AGONISTS | CENTESSA PHARMACEUTICALS (OREXIA) LIMITED (GB) | 2024-02-22 | — | — | WO | disclosed |
| WO-2024040245-A1 | PEPTIDE DERIVATIVES AND RELATED USES AS OREXIN AGONISTS | CENTESSA PHARMACEUTICALS (OREXIA) LIMITED (GB) | 2024-02-22 | — | — | WO | disclosed |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2021-04-01 | — | — | US | disclosed |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RAPAFUSYN PHARMACEUTICALS, INC. | 2020-02-06 | — | — | US | disclosed |
| US-9034798-B2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | CAPROTEC BIOANALYTICS GMBH (DE) | 2015-05-19 | — | — | US | disclosed |
| US-8569481-B2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2259068-B1 | Capture compounds and methods for analyzing the proteome | CAPROTEC BIOANALYTICS GMBH (DE) | 2013-08-14 | — | — | EP | disclosed |
| US-7858560-B2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | CAPROTEC BIOANALYTICS GMBH (DE) | 2010-12-28 | — | — | US | disclosed |
| EP-2259068-A2 | Capture compounds and methods for analyzing the proteome | caprotec bioanalytics GmbH (DE) | 2010-12-08 | — | — | EP | disclosed |
| US-20100298168-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | HK PHARMACEUTICALS, INC. | 2010-11-25 | — | — | US | disclosed |
| US-20100248264-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | HK PHARMACEUTICALS, INC. | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | KYNU 4187/4885KDM4E 3663/4885LMNA 4788/4885 |
| US-20250213735-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | KYNU 491/4885KDM4E 3543/4885LMNA 3809/4885 |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | KYNU 4187/4885KDM4E 3663/4885LMNA 4788/4885 |
| US-20240360175-A1 | PEPTIDE DERIVATIVES AND RELATED USES AS OREXIN AGONISTS | HCRTR2, HCRTR1, NPY1R | KYNU 1130/4885KDM4E 1159/4885LMNA 2529/4885 |
| US-20250277001-A1 | PEPTIDE DERIVATIVES AND RELATED USES AS OREXIN AGONISTS | HCRTR2, HCRTR1, CRH | KYNU 883/4885KDM4E 1786/4885LMNA 3078/4885 |
| US-20260116923-A1 | CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS | IL1A, IL1B, IL1RN | KYNU 3977/4885KDM4E 4319/4885LMNA 167/4885 |
| US-20100298168-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | CHLSN, PTMS, SRMS | KYNU 1725/4885KDM4E 3796/4885LMNA 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.